DexCom, Inc. (DXCM) PE Ratio: 32.32
Is DexCom, Inc.’s P/E ratio high or low?
DexCom, Inc.'s P/E ratio of 32.32 is 72% below its 5-year average of 113.61, near the low end of its 5-year range (24.71–271.20).
The P/E ratio for DexCom, Inc. (DXCM) is 32.32 as of Wednesday, June 10, 2026. It is below its 12-month average by 23.06% (42.00).
PE Ratio (32.32) = Close Price ($75.62) / Diluted TTM EPS ($2.34)
DXCM PE Ratio Chart
DXCM Average PE Ratio Chart
DXCM Current vs Average PE Ratio Chart
DXCM PE Ratio Metrics
PE RATIO
32.32
PE RATIO AVG TTM
42.00
PE RATIO AVG 3Y
71.55
PE RATIO AVG 5Y
113.61
PE RATIO AVG 10Y
136.04
PE RATIO AVG 15Y
136.04
PE RATIO AVG 20Y
136.04
CURRENT VS TTM AVG
-23.06%
CURRENT VS 3Y AVG
-54.83%
CURRENT VS 5Y AVG
-71.55%
CURRENT VS 10Y AVG
-76.24%
CURRENT VS 15Y AVG
-76.24%
CURRENT VS 20Y AVG
-76.24%
DXCM Competitors' PE Ratio
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.24B | 32.32 | 42.00 | 71.55 | 113.61 |
| Biogen Inc. (BIIB) | $29.00B | 21.05 | 16.53 | 18.50 | 18.66 |
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.72 | 25.98 | 29.31 | 38.48 |
| Medline Inc. (MDLN) | $30.90B | 30.20 | 31.64 | 31.64 | 31.64 |
| Veeva Systems Inc. (VEEV) | $26.73B | 29.19 | 47.10 | 54.65 | 66.86 |
| Centene Corporation (CNC) | $31.94B | N/A | 8.90 | 15.70 | 23.23 |
| Zoetis Inc. (ZTS) | $34.20B | 13.52 | 22.13 | 30.46 | 35.44 |
| Waters Corporation (WAT) | $23.83B | 46.49 | 31.91 | 30.92 | 30.43 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 26.50 | 31.99 | 32.80 | 36.44 |
| BioNTech SE (BNTX) | $21.81B | N/A | 55.73 | 22.62 | 82.47 |
P/E vs. its own history
At 32.3, P/E is cheaper than usual — richer than 4% of its 8-year range.
8-year low
24.7
median
140.7
8-year high
321.6
P/E Comparison
Trailing P/E
32.3
Forward P/E
24.5
Forward P/E Calculation
View All Analyst EstimatesForward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$75.62
Forward EPS (Est.)
$3.09
Forward P/E
24.50
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
DexCom, Inc. PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. PE Ratio FAQ
- What is the P/E ratio for DexCom, Inc. (DXCM)?
- The P/E ratio for DXCM stock is 32.32.
- Is DexCom, Inc.'s P/E ratio high or low?
- DexCom, Inc.'s P/E ratio of 32.32 is 72% below its 5-year average of 113.61, near the low end of its 5-year range (24.71–271.20).
- What is the TTM average P/E ratio for DexCom, Inc. (DXCM)?
- The TTM average P/E ratio for DXCM stock is 42.00.
- What is the 3Y average P/E ratio for DexCom, Inc. (DXCM)?
- The 3Y average P/E ratio for DXCM stock is 71.55.
- What is the 5Y average P/E ratio for DexCom, Inc. (DXCM)?
- The 5Y average P/E ratio for DXCM stock is 113.61.
- What is the 10Y average P/E ratio for DexCom, Inc. (DXCM)?
- The 10Y average P/E ratio for DXCM stock is 136.04.
- What is the 15Y average P/E ratio for DexCom, Inc. (DXCM)?
- The 15Y average P/E ratio for DXCM stock is 136.04.
- What is the 20Y average P/E ratio for DexCom, Inc. (DXCM)?
- The 20Y average P/E ratio for DXCM stock is 136.04.
DexCom, Inc. PE Ratio History
| DATE | PE RATIO |
|---|---|
| 2026-06-10 | 32.32 |
| 2026-06-09 | 33.41 |
| 2026-06-08 | 32.74 |
| 2026-06-05 | 31.14 |
| 2026-06-04 | 31.02 |
| 2026-06-03 | 31.10 |
| 2026-06-02 | 31.39 |
| 2026-06-01 | 32.00 |
| 2026-05-29 | 31.51 |
| 2026-05-28 | 30.91 |
| 2026-05-27 | 30.03 |
| 2026-05-26 | 30.77 |
| 2026-05-22 | 30.81 |
| 2026-05-21 | 30.73 |
| 2026-05-20 | 30.53 |
| 2026-05-19 | 28.61 |
| 2026-05-18 | 27.82 |
| 2026-05-15 | 26.34 |
| 2026-05-14 | 24.71 |
| 2026-05-13 | 25.03 |
| 2026-05-12 | 26.13 |
| 2026-05-11 | 25.35 |
| 2026-05-08 | 25.90 |
| 2026-05-07 | 26.03 |
| 2026-05-06 | 25.79 |
| 2026-05-05 | 25.42 |
| 2026-05-04 | 25.66 |
| 2026-05-01 | 26.22 |
| 2026-04-30 | 25.45 |
| 2026-04-29 | 27.41 |
| 2026-04-28 | 28.25 |
| 2026-04-27 | 29.24 |
| 2026-04-24 | 29.32 |
| 2026-04-23 | 29.86 |
| 2026-04-22 | 30.20 |
| 2026-04-21 | 29.81 |
| 2026-04-20 | 30.77 |
| 2026-04-17 | 30.47 |
| 2026-04-16 | 29.16 |
| 2026-04-15 | 29.30 |
| 2026-04-14 | 29.98 |
| 2026-04-13 | 30.06 |
| 2026-04-10 | 30.49 |
| 2026-04-09 | 31.28 |
| 2026-04-08 | 31.33 |
| 2026-04-07 | 30.05 |
| 2026-04-06 | 30.10 |
| 2026-04-02 | 29.63 |
| 2026-04-01 | 29.70 |
| 2026-03-31 | 29.90 |
| 2026-03-30 | 29.48 |
| 2026-03-27 | 29.64 |
| 2026-03-26 | 31.47 |
| 2026-03-25 | 31.83 |
| 2026-03-24 | 31.71 |
| 2026-03-23 | 31.40 |
| 2026-03-20 | 31.88 |
| 2026-03-19 | 32.03 |
| 2026-03-18 | 32.22 |
| 2026-03-17 | 32.06 |
| 2026-03-16 | 31.59 |
| 2026-03-13 | 30.59 |
| 2026-03-12 | 31.08 |
| 2026-03-11 | 31.58 |
| 2026-03-10 | 32.28 |
| 2026-03-09 | 32.73 |
| 2026-03-06 | 32.43 |
| 2026-03-05 | 33.66 |
| 2026-03-04 | 34.71 |
| 2026-03-03 | 34.80 |
| 2026-03-02 | 35.13 |
| 2026-02-27 | 34.97 |
| 2026-02-26 | 35.42 |
| 2026-02-25 | 34.84 |
| 2026-02-24 | 34.80 |
| 2026-02-23 | 34.89 |
| 2026-02-20 | 34.80 |
| 2026-02-19 | 34.41 |
| 2026-02-18 | 34.67 |
| 2026-02-17 | 33.54 |
| 2026-02-13 | 33.34 |
| 2026-02-12 | 30.99 |
| 2026-02-11 | 37.86 |
| 2026-02-10 | 37.87 |
| 2026-02-09 | 38.98 |
| 2026-02-06 | 38.87 |
| 2026-02-05 | 38.83 |
| 2026-02-04 | 39.34 |
| 2026-02-03 | 39.79 |
| 2026-02-02 | 40.29 |
| 2026-01-30 | 40.58 |
| 2026-01-29 | 41.11 |
| 2026-01-28 | 40.76 |
| 2026-01-27 | 40.93 |
| 2026-01-26 | 40.74 |
| 2026-01-23 | 40.48 |
| 2026-01-22 | 41.07 |
| 2026-01-21 | 40.06 |
| 2026-01-20 | 39.29 |
| 2026-01-16 | 38.63 |
| 2026-01-15 | 38.47 |
| 2026-01-14 | 38.72 |
| 2026-01-13 | 39.03 |
| 2026-01-12 | 39.43 |
| 2026-01-09 | 37.44 |
| 2026-01-08 | 38.02 |
| 2026-01-07 | 38.94 |
| 2026-01-06 | 38.83 |
| 2026-01-05 | 37.58 |
| 2026-01-02 | 36.97 |
| 2025-12-31 | 36.87 |
| 2025-12-30 | 37.26 |
| 2025-12-29 | 37.48 |
| 2025-12-26 | 37.54 |
| 2025-12-24 | 37.46 |
| 2025-12-23 | 37.14 |
| 2025-12-22 | 37.46 |
| 2025-12-19 | 36.70 |
| 2025-12-18 | 36.62 |
| 2025-12-17 | 36.53 |
| 2025-12-16 | 36.87 |
| 2025-12-15 | 36.52 |
| 2025-12-12 | 37.20 |
| 2025-12-11 | 38.30 |
| 2025-12-10 | 37.53 |
| 2025-12-09 | 36.85 |
| 2025-12-08 | 36.46 |
| 2025-12-05 | 36.38 |
| 2025-12-04 | 36.25 |
| 2025-12-03 | 36.03 |
| 2025-12-02 | 35.81 |
| 2025-12-01 | 35.29 |
| 2025-11-28 | 35.26 |
| 2025-11-26 | 34.74 |
| 2025-11-25 | 34.27 |
| 2025-11-24 | 34.56 |
| 2025-11-21 | 33.46 |
| 2025-11-20 | 32.46 |
| 2025-11-19 | 33.18 |
| 2025-11-18 | 33.43 |
| 2025-11-17 | 32.49 |
| 2025-11-14 | 32.26 |
| 2025-11-13 | 33.18 |
| 2025-11-12 | 33.12 |
| 2025-11-11 | 32.29 |
| 2025-11-10 | 30.47 |
| 2025-11-07 | 30.56 |
| 2025-11-06 | 32.23 |
| 2025-11-05 | 32.93 |
| 2025-11-04 | 33.99 |
| 2025-11-03 | 33.57 |
| 2025-10-31 | 32.34 |
| 2025-10-30 | 37.89 |
| 2025-10-29 | 47.35 |
| 2025-10-28 | 48.08 |
| 2025-10-27 | 49.05 |
| 2025-10-24 | 48.84 |
| 2025-10-23 | 49.35 |
| 2025-10-22 | 49.10 |
| 2025-10-21 | 48.44 |
| 2025-10-20 | 47.52 |
| 2025-10-17 | 46.25 |
| 2025-10-16 | 46.06 |
| 2025-10-15 | 45.42 |
| 2025-10-14 | 45.98 |
| 2025-10-13 | 45.28 |
| 2025-10-10 | 45.22 |
| 2025-10-09 | 47.28 |
| 2025-10-08 | 47.07 |
| 2025-10-07 | 45.85 |
| 2025-10-06 | 46.08 |
| 2025-10-03 | 46.56 |
| 2025-10-02 | 46.14 |
| 2025-10-01 | 45.89 |
| 2025-09-30 | 46.73 |
| 2025-09-29 | 46.15 |
| 2025-09-26 | 46.60 |
| 2025-09-25 | 47.43 |
| 2025-09-24 | 46.88 |
| 2025-09-23 | 47.36 |
| 2025-09-22 | 48.27 |
| 2025-09-19 | 46.84 |
| 2025-09-18 | 52.63 |
| 2025-09-17 | 53.08 |
| 2025-09-16 | 53.16 |
| 2025-09-15 | 52.49 |
| 2025-09-12 | 52.93 |
| 2025-09-11 | 52.78 |
| 2025-09-10 | 52.78 |
| 2025-09-09 | 54.44 |
| 2025-09-08 | 54.17 |
| 2025-09-05 | 55.91 |
| 2025-09-04 | 56.08 |
| 2025-09-03 | 54.81 |
| 2025-09-02 | 51.60 |
| 2025-08-29 | 52.32 |
| 2025-08-28 | 52.14 |
| 2025-08-27 | 53.04 |
| 2025-08-26 | 52.86 |
| 2025-08-25 | 52.75 |
| 2025-08-22 | 57.13 |
| 2025-08-21 | 55.99 |
| 2025-08-20 | 56.72 |
| 2025-08-19 | 56.18 |
| 2025-08-18 | 56.13 |
| 2025-08-15 | 56.22 |
| 2025-08-14 | 55.53 |
| 2025-08-13 | 55.53 |
| 2025-08-12 | 55.67 |
| 2025-08-11 | 54.06 |
| 2025-08-08 | 54.76 |
| 2025-08-07 | 53.06 |
| 2025-08-06 | 53.06 |
| 2025-08-05 | 52.40 |
| 2025-08-04 | 52.95 |
| 2025-08-01 | 55.06 |
| 2025-07-31 | 56.09 |
| 2025-07-30 | 61.85 |
| 2025-07-29 | 66.68 |
| 2025-07-28 | 66.81 |
| 2025-07-25 | 66.41 |
| 2025-07-24 | 64.73 |
| 2025-07-23 | 64.50 |
| 2025-07-22 | 63.52 |
| 2025-07-21 | 62.71 |
| 2025-07-18 | 62.60 |
| 2025-07-17 | 62.76 |
| 2025-07-16 | 62.78 |
| 2025-07-15 | 63.27 |
| 2025-07-14 | 63.68 |
| 2025-07-11 | 62.22 |
| 2025-07-10 | 63.78 |
| 2025-07-09 | 63.34 |
| 2025-07-08 | 62.51 |
| 2025-07-07 | 61.90 |
| 2025-07-03 | 61.89 |
| 2025-07-02 | 62.37 |
| 2025-07-01 | 62.37 |
| 2025-06-30 | 65.14 |
| 2025-06-27 | 64.43 |
| 2025-06-26 | 63.46 |
| 2025-06-25 | 63.19 |
| 2025-06-24 | 65.35 |
| 2025-06-23 | 59.58 |
| 2025-06-20 | 59.70 |
| 2025-06-18 | 60.46 |
| 2025-06-17 | 61.07 |
| 2025-06-16 | 61.94 |
| 2025-06-13 | 61.19 |
| 2025-06-12 | 61.83 |
| 2025-06-11 | 61.93 |
| 2025-06-10 | 63.30 |
| 2025-06-09 | 63.94 |
| 2025-06-06 | 64.68 |
| 2025-06-05 | 63.99 |
| 2025-06-04 | 63.89 |
| 2025-06-03 | 64.77 |
| 2025-06-02 | 63.81 |
| 2025-05-30 | 64.03 |
| 2025-05-29 | 63.33 |
Showing the most recent 260 of 1,660 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach